Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Charles Bankhead

Authored Items
Nivolumab Shows Durable Activity in Subgroups of Patients with Metastatic CRC
Charles Bankhead
TOP - August 2018, Vol 11, No 2 in Colorectal Cancer
Immunotherapy plus Targeted Therapy Combination Active in Metastatic CRC
Charles Bankhead
TOP - August 2018, Vol 11, No 2 in Immunotherapy
Mogamulizumab, Anti-CCR4 Antibody, Improves Survival in Patients with Advanced Cutaneous T-Cell Lymphoma
Charles Bankhead
Web Exclusives in Emerging Therapies
New BTK Inhibitor Leads to Durable Responses in Relapsed or Refractory Chronic Lymphocytic Leukemia
Charles Bankhead
Web Exclusives in Leukemia
High Response Rate with 3-Drug Combination for Untreated Follicular Lymphoma
Charles Bankhead
Web Exclusives in Lymphoma
Chemotherapy Use in Breast Cancer Declines with Use of MammaPrint Gene-Based Assay
Charles Bankhead
TOP - November 2016, Vol 9, No 4 in Breast Cancer
Increased Physical Activity May Help Extend Survival After Prostate Cancer Diagnosis
Charles Bankhead
TOP - May 2016, Vol 9, No 2 in Genitourinary Cancers
More Bad News for Erythropoiesis-Stimulating Agents in Chemotherapy-Induced Anemia
Charles Bankhead
TOP - May 2015, Vol 8, No 2 in Breast Cancer
Highest Response Rate to Date in mRCC With Pazopanib as Third-Line VEGF Inhibitor
Charles Bankhead
TOP - October 2014, Vol 7, No 4 in Genitourinary Cancers
PARP Inhibitor Veliparib Active in Recurrent BRCA-Positive Ovarian Cancer
Charles Bankhead
TOP - October 2014, Vol 7, No 4 in Gynecologic Cancers
Last modified: December 11, 2015